Tumor microenvironment parameters as a predictor of the duration of clinical effectiveness of immunotargeted therapy in advanced or metastatic endometrial cancer: A pilot multicenter observational study
Background. The inclusion of lenvatinib in the immunotherapy regimen for patients with MSS/pMMR endometrial cancer (EC) is due to its ability to modulate the tumor microenvironment, which allows the use of pembrolizumab in low-immunogenic tumors. However, only 30 % of patients with advanced or metas...
Saved in:
Main Authors: | A. A. Maltseva, A. Yu. Kalinchuk, N. V. Krakhmal, N. M. Chernorubashkina, E. S. Martynova, R. A. Zukov, A. A. Gofman, A. B. Villert, O. N. Churuksaeva, L. A. Kolomiets, L. A. Tashireva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2024-05-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1213 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical and morphological features in patients with advanced endometrial cancer treated with immunotargeting therapy
by: L. A. Kolomiets, et al.
Published: (2023-08-01) -
Efficient sequence of therapy for advanced and metastatic endometrial cancer
by: A. A. Rumyantsev
Published: (2022-09-01) -
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01) -
COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01) -
Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01)